WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
The PIPE offering consists of 36,190,476 units
We have big plans across our B2C and B2B businesses in India and abroad
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
This will lead to the consolidation and optimization of the company's operations related to the manufacturing of ampoules and vials
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Aster commits to increase bed capacity in the State via capacity expansion and greenfield projects
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Subscribe To Our Newsletter & Stay Updated
.JPG)
